TerminatedPhase 2

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Stopped: The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.

United States260 participantsStarted 2018-09-11

Plain-language summary

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of urothelial carcinoma * Adequate bone marrow and organ function Exclusion Criteria: * Uncontrolled tumor in the brain * Unacceptable toxicity with prior checkpoint inhibitor * Impaired heart function

What they're measuring

Objective Response Rate (ORR)

Timeframe: Up to approximately 3 years

Trial details

NCT IDNCT03606174

SponsorMirati Therapeutics Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-08-03

Results submitted2023-08-03

View on ClinicalTrials.gov More Urothelial Carcinoma trials